Short answer
GLAUKOS Corp (GKOS) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor Presentation intended for recurring use with investors and stakeholders.
GLAUKOS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor Presentation intended for recurring use with investors and stakeholders
- Presentation available on Glaukos’ investor-relations website
- Exhibit 99.1 contains the substantive investor materialsրանց
Item EX-99.1 · Exhibit EX-99.1
- Investor presentation outlines 13 pipeline programs and 12 commercialized products across glaucoma, cornea, retina and anterior-segment pharmaceuticals
- 2025 sales grew 30%, with 10-year revenue CAGR of 20% and $900 million invested in R&D since 2018
- Epioxa launched commercially in March 2026, creating a new growth platform for FDA-approved epithelium-on keratoconus treatment
- iDose TR received FDA re-administration approval in January 2026, supporting recurring procedural-pharmaceutical revenue
- 2026 revenue guidance midpoint $690 million, with 2Q 2026 non-GAAP gross margin of 85% and $289 million cash, no debt as of June 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GLAUKOS Corp 8-K filings
Get the next GKOS 8-K as it lands
Follow GKOS for push alerts, or ask the research agent what this filing means.